WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Independent UN experts urge Yemen’s Houthis to free detained Baha'i followers
Iowa lawmakers approve bill just in time to increase compensation for Boy Scout abuse victims
South Africa man convicted in deaths of 2 Alaska Native women faces revocation of U.S. citizenship
New York Rangers captain Jacob Trouba may be the most interesting man in hockey, on and off the ice
Judge blocks Biden administration from enforcing new gun sales background check rule in Texas
Rangers option rookie Jack Leiter 1 day after he allowed 7 runs in his major league debut
New York Rangers captain Jacob Trouba may be the most interesting man in hockey, on and off the ice
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/18/2024
Culture festival showcases integration
Lottery 'loser' boyfriend, 39, who is fighting his ex
Jude Bellingham's new model girlfriend Laura Celia Valk looks sensational in a figure
Dalai Lama’s sister receives award for educating Tibetans in exile — Radio Free Asia